Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC).Himisha Beltran, Noura J. Choudhury, Melissa L. Johnson et al.|Journal of Clinical Oncology|2024Cited by 37
Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).Himisha Beltran, Noura J. Choudhury, Prantesh Jain et al.|Journal of Clinical Oncology|2024Cited by 30
OA10.06 Impact of Brain Metastases on Safety and Efficacy of MK-6070, a DLL3-Targeting T Cell Engager, in Small Cell Lung CancerNoura J. Choudhury, Prantesh Jain, Himisha Beltran et al.|Journal of Thoracic Oncology|2024Cited by 12
2758MO Updated results from a phase I/II study of gocatamig for small cell lung cancer (SCLC) and other neuroendocrine cancersHimisha Beltran, A.J. Cooper, M.L. Johnson et al.|Annals of Oncology|2025Cited by 6
656 A phase 1/2 trial in progress of MK-6070 (aka HPN328), a DLL3-targeting T cell engager, as monotherapy or combination therapy for advanced cancers associated with DLL3 expressionPrantesh Jain, Himisha Beltran, Alissa J. Cooper et al.|Regular and Young Investigator Award Abstracts|2024Cited by 2